GlassScriptPhysician profile
Lindsay E Conger
NPI 1508346099
$4,532.41
in general payments reported to CMS, 2019-2025
18 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $560 · 2023: $958 · 2024: $966 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $694.97 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $599.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $475.81 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $450.15 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $423.85 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $297.73 | 2021-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $288.44 | 2023-2025 | Azstarys |
| Lundbeck LLC | $222.08 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $214.13 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $140.86 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $128.41 | 2021-2024 | Jornay Pm |
| Almatica Pharma LLC | $126.37 | 2022-2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $107.51 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $104.18 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $95.39 | 2023 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77.59 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $60.17 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $24.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Conger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.